Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part III)

Qing Liu, Karl E. Peace

Research output: Contribution to journalArticlepeer-review

Abstract

Part III of the article that describes confirmatory adaptive platform trial (CAPT) design for COVID-19 treatment development. We continue with the section on statistical methods for CAPT design, covering topics on sequential p-value and monitoring, point estimate and confidence interval, multiplicity in hypothesis testing, missing data handling, and use of non-concurrent controls. We finish the article with discussion on controversy of stochastic curtailment, inappropriateness of adaptive Bayesian design, and free software for group sequential designs.

Original languageAmerican English
JournalLinkedIn
StatePublished - May 11 2020

DC Disciplines

  • Biostatistics
  • Environmental Public Health
  • Epidemiology
  • Public Health

Fingerprint

Dive into the research topics of 'Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part III)'. Together they form a unique fingerprint.

Cite this